X. Pivot

发表

Landscape of somatic mutations in 560 breast cancer whole genome sequences

David C. Jones, E. Birney, M. Ringnér, 2016, Nature.

International network of cancer genome projects

Gary D Bader, Benjamin J. Raphael, Joshua M. Stuart, 2010, Nature.

Prospective study of the impact of using the 21-gene recurrence score assay on clinical decision making in women with estrogen receptor-positive, HER2-negative, early-stage breast cancer in France.

A. Roquancourt, R. Rouzier, F. Penault-Llorca, 2012 .

Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review

X. Pivot, C. Borg, F. Fiteni, 2014, Cancer medicine.

Pan-cancer analysis of whole genomes

Steven J. M. Jones, Nuno A. Fonseca, Icgc, 2020, Nature.

Malnutrition is an independent factor associated with nosocomial infections.

E. Van Obberghen, X. Pivot, S. Schneider, 2004, The British journal of nutrition.

First description of a double heterozygosity for BRCA1 and BRCA2 pathogenic variants in a French metastatic breast cancer patient: A case report.

X. Pivot, M. Collonge-Rame, J. Neidich, 2017, Oncology reports.

Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer.

G. Lyman, G. Curigliano, X. Pivot, 2019, European journal of cancer.

Follow-up of patients with localized breast cancer and first indicators of advanced breast cancer recurrence: A retrospective study.

X. Pivot, F. Fiteni, J. Viot, 2017, Breast.

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

Saeed Sadeghi, Allison Florance, H. Gómez, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

P. Fasching, P. Neven, F. Esteva, 2020, Breast.

Combining molecular targeted therapies: clinical experience

M. Espié, M. Marty, X. Pivot, 2011, Anti-cancer drugs.

Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis

A. Urruticoechea, X. Pivot, V. Diéras, 2020, Breast Cancer Research and Treatment.

Influence of capecitabine absorption on its metabolites pharmacokinetics: a bioequivalence study.

X. Pivot, C. Borg, M. Demarchi, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer.

N. Magné, G. Poissonnet, O. Dassonville, 2005, Oral oncology.

Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II study.

G. Poissonnet, P. Marcy, O. Dassonville, 1998, International journal of radiation oncology, biology, physics.

Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma

X. Pivot, D. Montange, B. Royer, 2014, Cancer Chemotherapy and Pharmacology.

Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer.

J. Jassem, X. Pivot, H. Chung, 2009, European journal of cancer.

Phase II Trial of a Paclitaxel-Carboplatin Combination in Recurrent Squamous Cell Carcinoma of the Head and Neck

X. Pivot, P. Guerrier, D. Cupissol, 2000, Oncology.

Anti-MUC1-C Antibody-Conjugated Nanoparticles Potentiate the Efficacy of Fractionated Radiation Therapy.

O. Tillement, X. Pivot, D. Kufe, 2020 .

Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience.

A. Cesne, A. Le Cesne, X. Pivot, 1998, British Journal of Cancer.

Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up.

L. Zelek, P. Terrier, A. Cesne, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Squamous cell carcinoma of the head and neck: ESMO clinical Recommendations for diagnosis, treatment and follow-up.

E. Felip, X. Pivot, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab

M. Derde, T. Petit, X. Pivot, 2021, PloS one.

Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer—Study BES 06

G. Romieu, X. Pivot, M. Demarchi, 2013, Targeted Oncology.

Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study.

X. Pivot, K. Jung, B. Ataseven, 2018, The oncologist.

Correction to: Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3

G. Lyman, X. Pivot, D. Lüftner, 2020, Targeted Oncology.

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study.

L. Zelek, A. Ballestrero, L. Fallowfield, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.

X. Pivot, F. Bidard, J. Pierga, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Discordance in early breast cancer for tumour grade, estrogen receptor, progesteron receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumour.

X. Pivot, J. Sautière, Thierry Nguyen, 2011, Breast.

Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.

J. Jassem, A. Wardley, X. Pivot, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Retrospective Study of Bifractionated CPT-11 With LF5FU Infusion (FOLFIRI-3) in Colorectal Cancer Patients Pretreated With Oxaliplatin and CPT-11 Containing Chemotherapies

X. Pivot, C. Borg, Thierry Nguyen, 2008, American journal of clinical oncology.

Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer

X. Pivot, M. Woronoff-lemsi, L. Chaigneau, 2006, The European Journal of Health Economics.

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

D. Miles, L. Dirix, G. Romieu, 2013, British Journal of Cancer.

MAINTENANCE HORMONAL TREATMENT IMPROVES PROGRESSION FREE SURVIVAL AFTER A FIRST LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC BREAST CANCER

C. Tournigand, X. Pivot, A. de Gramont, 2008, International journal of medical sciences.

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.

L. Fallowfield, M. Aapro, F. Puglisi, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Awareness and Misconceptions of Breast Cancer Risk Factors Among Laypersons and Physicians

X. Pivot, S. Couraud, J. Morère, 2018, Current Oncology Reports.

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.

B. Xu, X. Pivot, J. Pierga, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Real-world clinical profile, treatment patterns and patient-reported outcomes in a subset of HR+/HER2- advanced breast cancer patients with poor prognostic factors: data from an international study

F. Ringeisen, X. Pivot, A. Rider, 2021, ESMO open.

Mammography utilization in women aged 40–49 years: the French EDIFICE survey

J. Blay, X. Pivot, J. Morère, 2011, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial

J. Ahn, B. Melichar, X. Pivot, 2019, JAMA oncology.

Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO.

A. Schneeweiss, D. Miles, X. Pivot, 2011, European journal of cancer.

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

R. Greil, F. André, V. Semiglazov, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.

M. Parmar, J. Mackey, D. Cameron, 2013, The Lancet. Oncology.

The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC.

L. Dirix, X. Pivot, C. Twelves, 2021, Clinical breast cancer.

Ki67 Assessment By qRT-PCR In OncotypeDx® Breast Recurrent Score®: Low Correlation With Immunohistochemistry Assessment of Ki67 And Prognostic Impact of Ki67 RNA Level of Expression.

X. Pivot, C. Borg, M. Paillard, 2021 .

Fluctuating Behavior of the French Population in Cancer Screening: 5th Edition of the EDIFICE Survey

X. Pivot, S. Couraud, C. Touboul, 2018, Current Oncology Reports.

Cancer screening tests in France: First results of EDIFICE study.

X. Pivot, J. Blay, D. Serin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study.

J. Machiels, M. Campone, X. Pivot, 2011, European journal of cancer.

Cabazitaxel

X. Pivot, Thierry Nguyen, Stefano Kim, 2011, Drugs.

Breast cancer screening in France: results of the EDIFICE survey

M. Namer, X. Pivot, S. Dolbeault, 2008, International journal of medical sciences.

Impact of organised programs on colorectal cancer screening

J. Blay, M. Namer, X. Pivot, 2008, BMC Cancer.

Cancer screening in France: subjects’ and physicians’ attitudes

J. Blay, M. Namer, X. Pivot, 2007, Cancer Causes & Control.

Emilia: use cunning to survive cancer.

X. Pivot, J. Gligorov, S. Richard, 2018, Chinese clinical oncology.

Is there still a role for triple endoscopy as part of staging for head and neck cancer?

X. Pivot, C. Villanueva, L. Chaigneau, 2006, Current opinion in otolaryngology & head and neck surgery.

Is routine triple endoscopy for head and neck carcinoma patients necessary in light of a negative chest computed tomography scan?

G. Poissonnet, P. Marcy, O. Dassonville, 2004, Cancer.

Impact of Chemotherapy Beyond the Third Line in Patients With Recurrent Epithelial Ovarian Cancer

X. Pivot, E. Kalbacher, M. Demarchi, 2015, International Journal of Gynecologic Cancer.

Screening for prostate cancer: growth without control

J. Blay, X. Pivot, J. Morère, 2011, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report.

X. Pivot, C. Borg, Thierry Nguyen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prostate cancer screening: contrasting trends

X. Pivot, J. Blay, C. Touboul, 2015, Cancer Causes & Control.

Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2− advanced breast cancer in five European countries

F. Ringeisen, X. Pivot, A. Davie, 2020, BMC cancer.

Increasing Coverage Rates for Mammographic Screening in France in Older Women––16 Years of Follow‐Up

J. Blay, X. Pivot, F. Beck, 2011, The breast journal.

Organized colorectal cancer screening programmes: how to optimize efficiency among general practitioners

X. Pivot, F. Eisinger, J. Viguier, 2011, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Liposomal encapsulation of trans-crocetin enhances oxygenation in patients with COVID-19-related ARDS receiving mechanical ventilation

X. Pivot, O. Collange, Z. Huang, 2021, Journal of Controlled Release.

Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy

X. Pivot, C. Borg, F. Fiteni, 2014, BMC Gastroenterology.

Biologic Drug Quality Assurance to Optimize HER2 + Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3

G. Lyman, X. Pivot, D. Lüftner, 2020, Targeted Oncology.

Specific anticancer treatments in the last 3 months of life: a French experience

X. Pivot, E. Kalbacher, C. Villanueva, 2013, Supportive Care in Cancer.

Efficacy and safety of ixabepilone, a novel epothilone analogue.

X. Pivot, A. Dufresne, C. Villanueva, 2007, Clinical breast cancer.

Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer

B. Chauffert, X. Pivot, M. Demarchi, 2009, World journal of surgical oncology.

Duration: escalation study of oral etoposide with carboplatin in patients with varied solid tumors

X. Pivot, E. Kalbacher, Thierry Nguyen, 2010, Anti-cancer drugs.

Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics

R. Paridaens, A. Jager, J. Verweij, 2019, Breast Cancer Research and Treatment.

A Retrospective Study of First Indicators of Breast Cancer Recurrence

G. Hortobagyi, R. Theriault, A. Buzdar, 2000, Oncology.

Breast cancer screening in women aged 50–74 years: isthereroom for improvement?

J. Blay, X. Pivot, J. Morère, 2011, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Ixabepilone: A New Active Chemotherapy in the Treatment of Breast Cancer

X. Pivot, M. Demarchi, C. Villanueva, 2009, Women's health.

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.

H. Gómez, Bing-he Xu, M. Campone, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevention and screening

S. Duffy, A. Carrato, M. Kusumoto, 2012 .

[Cost effectiveness of Ligasure Precise versus surgical clips during axillary nodal dissection for breast cancer].

X. Pivot, J. Sautière, D. Riethmuller, 2006, Journal de gynecologie, obstetrique et biologie de la reproduction.

Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer

N. Ibrahim, X. Pivot, M. Pegram, 2010, British Journal of Cancer.

Milestones over the development of SB3, a trastuzumab biosimilar.

I. Bondarenko, X. Pivot, E. Curtit, 2018, Future oncology.

Long-term follow-up of patients with metastatic breast cancer treated by trastuzumab: impact of institutions.

X. Pivot, F. Fiteni, P. Montcuquet, 2014, Breast.

First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: Cost-minimization analysis

X. Pivot, F. Fiteni, P. Montcuquet, 2014, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Role of STAT3 in CD4+CD25+FOXP3+ Regulatory Lymphocyte Generation: Implications in Graft-versus-Host Disease and Antitumor Immunity1

P. Rohrlich, X. Pivot, J. Pallandre, 2007, The Journal of Immunology.

Antitumor Immunity Implications in Graft-versus-Host Disease Regulatory Lymphocyte Generation : + FOXP 3 + CD 25 + Role of STAT 3 in CD 4

P. Rohrlich, X. Pivot, J. Pallandre, 2007 .

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Treatment-Induced Acute Leukaemia after Major Response to Cyclophosphamide-Based Metronomic Chemotherapy in Refractory Heavily Pre-Treated Prostate Cancer

X. Pivot, C. Borg, Thierry Nguyen, 2013 .

Dendritic cell and natural killer cell cross-talk: a pivotal role of CX3CL1 in NK cytoskeleton organization and activation.

L. Zitvogel, B. Ryffel, J. Strominger, 2008, Blood.

Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine

F. Marmé, X. Pivot, S. Im, 2018, Breast Cancer.

Phase II trial of paclitaxel and uracil--tegafur in metastatic breast cancer. TEGATAX trial.

X. Pivot, M. Demarchi, A. Dufresne, 2011, Breast.

Prognostic F actors i n P rimary B reast S arcomas: A S eries o f Patients W ith L ong-Term F ollow-Up

L. Zelek, P. Terrier, A. Cesne, 2003 .

In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial

P. Morel, X. Pivot, P. Tiberghien, 2018, Oncoimmunology.

[Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France].

M. Espié, X. Pivot, J. Pierga, 2012, Bulletin du cancer.

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.

P. Fasching, P. Neven, F. Esteva, 2019, The New England journal of medicine.

HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.

Sung-Bae Kim, Shou‐Tung Chen, J. Ahn, 2016, European journal of cancer.

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

Arlene Chan, Andreas Schneeweiss, Luc Y Dirix, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer

D. Amadori, H. Rugo, M. Campone, 2013, Breast Cancer Research and Treatment.

First-line bevacizumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimisation analysis.

X. Pivot, C. Villanueva, L. Chaigneau, 2012, Anticancer research.

[Immunotherapy: an emerging strategies against prostate castration resistant cancer].

F. Kleinclauss, X. Pivot, C. Borg, 2012, Bulletin du cancer.

Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab

X. Pivot, B. Degano, D. Vernerey, 2022, Frontiers in Cardiovascular Medicine.

Ki67 Assessment by qRT-PCR in OncotypeDx ® Breast Recurrent Score®: Low Correlation With IHC Assessment of ki67 and Prognostic Impact of ki67 RNA Level of Expression.

X. Pivot, C. Borg, M. Paillard, 2021 .

Intraoperative chemotherapy with cisplatin and epinephrine after cytoreductive surgery in patients with recurrent ovarian cancer: a phase I study

B. Chauffert, X. Pivot, M. Demarchi, 2010, Anti-cancer drugs.

Cisplatin Nephrotoxicity: A Multivariate Analysis of Potential Predisposing Factors

X. Pivot, G. Milano, J. Ferrero, 1997, Pharmacotherapy.

Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study.

L. Fallowfield, S. Verma, X. Pivot, 2017, European journal of cancer.

Abstract P4-12-11: Patient preference for subcutaneous trastuzumab via handheld syringe versus intravenous infusion in HER2-positive early breast cancer: Cohort 2 of the PrefHer study

L. Fallowfield, G. Curigliano, S. Verma, 2013 .

Phase I and pharmacokinetic study of capecitabine and cisplatin in head and neck cancer patients

X. Pivot, G. Milano, E. Chamorey, 2001 .

Phase III, randomized study of trastuzumab emtansine (T-DM1) {+/-} pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.

E. Perez, P. Ellis, W. Eiermann, 2015 .

Population Pharmacokinetics and Dosing Recommendations for Cisplatin during Intraperitoneal Peroperative Administration

B. Chauffert, X. Pivot, J. Kantelip, 2009, Clinical pharmacokinetics.

Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer

B. Chauffert, X. Pivot, D. Montange, 2008, Cancer Chemotherapy and Pharmacology.

Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding

B. Chauffert, X. Pivot, J. Kantelip, 2005, Anti-cancer drugs.

Clinical activity of the novel epothilone B analog, ixabepilone, in triple negative breast cancer (BC) patients

X. Pivot, A. Llombart-Cussac, Miguel Martín, 2008 .

Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): Results from MONALEESA-3.

P. Fasching, P. Neven, F. Esteva, 2018 .

Adjuvant T-DM1 versus Trastuzumab in Patients with Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer: Subgroup Analyses from KATHERINE.

C. Geyer, N. Wolmark, S. Loibl, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients with recurrent head and neck cancer.

C. Penning, Y. Humblet, X. Pivot, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Persistent taxane‐induced neuropathy in elderly patients treated for localized breast cancer

T. Petit, X. Pivot, M. Velten, 2020, The breast journal.

Anticancer therapy in patients with porphyrias: evidence today

X. Pivot, Thierry Nguyen, M. Demarchi, 2008, Expert opinion on drug safety.

LEAF- 4L6715 enhances oxygenation in patients with acute respiratory distress syndrome (ARDS) due to severe COVID-19: Final results of a phase I/II clinical trial

X. Pivot, O. Collange, A. Detappe, 2022, medRxiv.

Extravasation of liposomal doxorubicin induces irritant reaction without vesicant injury.

X. Pivot, Thierry Nguyen, M. Demarchi, 2012, Anticancer research.

Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients.

N. Magné, X. Pivot, G. Milano, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer

P. Neven, G. Sledge, S. Johnston, 2021, Clinical Cancer Research.

Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance.

N. Magné, X. Pivot, G. Milano, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Combination of Cisplatin‐Doxorubicin‐Cyclophosphamide in Adenocarcinoma of Unknown Primary Site: A Phase II Trial

N. Magné, X. Pivot, A. Thyss, 2001, American journal of clinical oncology.

Impact of COVID‐19 and lockdown regarding blood transfusion

X. Pivot, O. Collange, C. Gachet, 2021, Transfusion.

A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial.

X. Pivot, J. Pierga, I. Smith, 2014, Breast.

A French prospective pilot study for identifying dihydropyrimidine dehydrogenase (DPD) deficiency in breast cancer patients (pts) receiving capecitabine (cap)

F. Pinguet, J. Bonneterre, G. Romieu, 2013 .

Classic cytotoxic drugs: a narrow path for regulatory approval.

X. Pivot, 2017, The Lancet. Oncology.

Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy

F. Marmé, X. Pivot, A. Wolfer, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of squamous cell carcinoma of the head and neck (SCCHN).

V. Kataja, X. Pivot, S. Jelić, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy impairs skeletal muscle mitochondrial homeostasis in early breast cancer patients

X. Pivot, T. Hureau, B. Gény, 2022, Journal of cachexia, sarcopenia and muscle.

Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer

A. Schneeweiss, M. Parmar, J. Mackey, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract S1-01: Analysis of molecular prognostic factors associated with tumor immune and stromal microenvironment in BEATRICE, an open-label phase 3 trial in early triple-negative breast cancer (eTNBC)

P. Hegde, M. Parmar, J. Mackey, 2016 .

Anthracycline-resistant breast cancer

G. Hortobagyi, X. Pivot, L. Asmar, 1997, Breast cancer.

Special Lecture Anthracycline-Resistant Breast Cancer

G. Hortobagyi, X. Pivot, L. Asmar, 1997 .

Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: final analysis of the randomised, two-cohort PrefHer study

L. Fallowfield, S. Verma, X. Pivot, 2016 .

Total pathologic complete response (tpCR) and event-free survival (EFS) with subcutaneous (SC) or intravenous (IV) trastuzumab in HER2-positive early breast cancer (EBC).

J. Ahn, B. Melichar, X. Pivot, 2015 .

Wound healing is not impaired by the epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib

N. Magné, F. Demard, X. Pivot, 2003 .

Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2-targeted treatments: Results from the french personalized reimbursement model database (2011-2018).

X. Pivot, P. Cottu, N. Chalabi, 2020, European journal of cancer.

Renal safety of ibandronate 6 mg infused over 15 min versus 60 min in breast cancer patients with bone metastases: a randomized open-label equivalence trial.

X. Pivot, L. Frimat, E. Pujade-Lauraine, 2011, Breast.

Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients

X. Pivot, G. Milano, F. Dalenc, 2021, Cancer Chemotherapy and Pharmacology.

Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study.

B. Melichar, X. Pivot, C. Jackisch, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer

X. Pivot, Y. Merrouche, M. Woronoff-lemsi, 2006, Supportive Care in Cancer.

S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2−positive locally recurrent/metastatic breast cancer (LR/mBC)

R. Greil, F. André, V. Semiglazov, 2011 .

Phase II trial of ixabepilone in patients with metastatic breast cancer (MBC) who are resistant to an anthracycline, a taxane and capecitabine.

E. Perez, G. Hortobagyi, L. Bosserman, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial.

L. Fallowfield, G. Curigliano, S. Verma, 2017, Breast.

A phenotypic and mechanistic perspective on heterogeneity of HER2-positive breast cancers

D. Birnbaum, A. Viari, I. Pauporté, 2016, Molecular & cellular oncology.

Impact of awareness of cancer among acquaintances on cancer screening attendance

J. Blay, X. Pivot, J. Morère, 2011, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Economic impact of prescribing error prevention with computerized physician order entry of injectable antineoplastic drugs

P. Rohrlich, X. Pivot, M. Demarchi, 2013, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Computerized physician order entry of injectable antineoplastic drugs: An epidemiologic study of prescribing medication errors

C. Villanueva, V. Nerich, S. Limat, 2010, Int. J. Medical Informatics.

Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.

X. Pivot, P. Montcuquet, L. Mansi, 2013, The oncologist.

Analysis of Spontaneous Tumor-Specific CD4 T-cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes: Potential Synergistic Effect with Chemotherapy Response

E. Tartour, A. Cazes, X. Pivot, 2012, Clinical Cancer Research.

Cancer Therapy : Clinical Analysis of Spontaneous Tumor-Speci fi c CD 4 T-cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes : Potential Synergistic Effect with Chemotherapy Response

E. Tartour, X. Pivot, C. Borg, 2012 .

Docetaxel chemotherapy induces transverse superficial loss of the nail plate.

X. Pivot, A. Llombart-Cussac, M. Spielmann, 1997, Archives of dermatology.

A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2‐positive early breast cancer

S. Verma, N. Hauser, X. Pivot, 2016, Cancer medicine.

Leveraging Immunotherapy with Nanomedicine

X. Pivot, J. Goetz, A. Detappe, 2020, Advanced Therapeutics.

Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients

S. Urien, X. Pivot, E. Brain, 2004, Cancer Chemotherapy and Pharmacology.

Report of a young man with three successive curable cancers.

X. Pivot, J. Droz, M. Pavić, 2008, European journal of internal medicine.

Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial

F. Kleinclauss, X. Pivot, C. Borg, 2016, Medical Oncology.

Molecularly targeted agents: their promise as cancer chemopreventive interventions.

J. Soria, X. Pivot, J. Spano, 2005, European journal of cancer.

First description of a sporadic breast cancer in a woman with BRCA1 germline mutation

O. Mariani, A. Vincent-Salomon, M. Stern, 2015, Oncotarget.

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

E. Perez, P. Ellis, W. Eiermann, 2019, BMC Cancer.

Patterns of somatic structural variation in human cancer genomes

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2020, Nature.

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

P. Neven, G. Sledge, S. Johnston, 2019, JAMA oncology.

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.

P. Fasching, P. Neven, F. Esteva, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.

P. Neven, G. Sledge, X. Pivot, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

E. Perez, P. Ellis, W. Eiermann, 2019, BMC Cancer.

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study

E. Perez, P. Ellis, W. Eiermann, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pertuzumab monotherapy following trastuzumab-based treatment: Activity and tolerability in patients with advanced HER2- positive breast cancer.

K. Gelmon, J. Baselga, J. Cortes, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2020, Nature Communications.

Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).

P. Petrow, S. Culine, X. Pivot, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences

E. Birney, M. Ringnér, A. Børresen-Dale, 2019, Nature.

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers

Alain Viari, Thomas Bachelot, Michael R. Stratton, 2016, Nature Communications.

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?

S. Culine, X. Pivot, J. Douillard, 2007, British Journal of Cancer.

An analysis of potential factors allowing an individual prediction of cisplatin-induced anaemia.

N. Magné, X. Pivot, G. Milano, 2000, European journal of cancer.

Efficacy of trabectedin in metastatic solitary fibrous tumor

X. Pivot, E. Kalbacher, A. Thiery-Vuillemin, 2011, Rare tumors.

Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer.

X. Pivot, C. Borg, Stefano Kim, 2013, Clinical colorectal cancer.

Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma.

F. Kleinclauss, X. Pivot, M. Paillard, 2014 .

Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.

X. Pivot, N. Dohollou, J. Gligorov, 2011, European journal of cancer.

Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells.

X. Pivot, J. Pallandre, J. Rémy-Martin, 2011, Cancer research.

Microenvironment and Immunology Novel Role for STAT 3 in Transcriptional Regulation of NK Immune Cell Targeting Receptor MICA on Cancer Cells

X. Pivot, J. Rémy-Martin, C. Grandclément, 2011 .

Ixabepilone, a novel epothilone analog in the treatment of breast cancer

X. Pivot, C. Borg, Thierry Nguyen, 2008 .

A Randomized Phase I Study Comparing the Pharmacokinetics of HD201, a Trastuzumab Biosimilar, With European Union-sourced Herceptin.

J. Deslypere, X. Pivot, M. Kim, 2018, Clinical therapeutics.

Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE

E. Perez, P. Ellis, W. Eiermann, 2019, Cancer.

Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.

N. Harbeck, D. Miles, L. Dirix, 2008 .

Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4+CD25- T lymphocytes.

B. Ryffel, P. Rohrlich, X. Pivot, 2007, Experimental hematology.

Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.

E. Perez, G. Hortobagyi, L. Bosserman, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.

X. Pivot, M. Marty, 2008, European journal of cancer.

Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort

H. Blanché, M. Mathieu, H. Bonnefoi, 2017, npj Breast Cancer.

Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors for Patients with Advanced Gastrointestinal Stromal Tumors

J. Blay, X. Pivot, C. Borg, 2016, Clinical Drug Investigation.

Added value of molecular targeted agents in oncology.

J. Blay, J. Soria, D. Khayat, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety profile of new anticancer drugs

X. Pivot, Thierry Nguyen, M. Demarchi, 2010, Expert opinion on drug safety.

Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes

G. Thomas, D. Cox, H. Blanché, 2016, Breast Cancer Research.

Clinical benefit of bevacizumab (BV) plus first-line docetaxel (D) in elderly patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC): AVADO study.

S. Verma, D. Miles, X. Pivot, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A unified definition of clinical anthracycline resistance breast cancer

V. Valero, A. Buzdar, X. Pivot, 2000, British Journal of Cancer.

Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients.

M. Espié, X. Pivot, J. Pierga, 2011, British journal of clinical pharmacology.

Cytoreductive Surgery and Intraperitoneal Chemotherapy in Advanced Serous Epithelial Ovarian Cancer: A 14-Year French Retrospective Single-Center Study of 124 Patients

B. Chauffert, X. Pivot, E. Kalbacher, 2022, Annals of Surgical Oncology.

Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer

X. Pivot, M. Paillard, B. Royer, 2019, BMC Cancer.

New advances in DPYD genotype and risk of severe toxicity under capecitabine

F. Pinguet, C. Béroud, A. V. van Kuilenburg, 2017, PloS one.

Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: Results from MONALEESA-3.

P. Fasching, P. Neven, X. Pivot, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

G. Poissonnet, O. Dassonville, F. Demard, 2022 .

Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 Trial.

H. Gómez, S. Johnston, X. Pivot, 2009 .

Results of PONDx, a prospective multicenter study of the Oncotype DX® breast cancer assay: Real-life utilization and decision impact in French clinical practice.

X. Pivot, S. Dewas, E. Curtit, 2019, Breast.

In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?

P. Febbo, X. Pivot, S. Butler, 2014, The oncologist.

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

H. Iwata, N. Harbeck, T. Tabei, 2010, Breast Cancer Research and Treatment.

Hemodialysis does not affect everolimus pharmacokinetics: two cases of patients with metastatic renal cell cancer.

X. Pivot, D. Montange, B. Royer, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of sunitinib pharmacokinetic monitoring in a patient with metastatic renal cell carcinoma undergoing hemodialysis.

X. Pivot, E. Kalbacher, D. Montange, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX® Breast Recurrence Score Assay.

X. Pivot, J. Sautière, L. Mansi, 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy.

N. Magné, G. Poissonnet, O. Dassonville, 2001, European journal of cancer.

Impact of chemotherapy beyond the first line in patients with metastatic breast cancer

Christophe Tournigand, C. Tournigand, X. Pivot, 2007, Breast Cancer Research and Treatment.

Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study.

R. Rouzier, F. Penault-Llorca, A. de Roquancourt, 2015, The oncologist.

A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study

X. Pivot, B. Degano, D. Vernerey, 2017, BMC Cancer.

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

S. Margolin, M. Desilvio, V. Semiglazov, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

J. Baselga, S. Swain, X. Pivot, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer

F. Bertucci, X. Pivot, P. Viens, 2017, Cancer research and treatment : official journal of Korean Cancer Association.

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.

K. Gelmon, J. Baselga, J. Albanell, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer.

J. Blay, X. Pivot, F. Peyrade, 2004, European journal of cancer.

Results of randomised phase II studies comparing S16020 with methotrexate in patients with recurrent head and neck cancer.

F. Caponigro, X. Pivot, A. Awada, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck

E. Raymond, X. Pivot, J. Armand, 2001, British Journal of Cancer.

Clinical Prognostic Factors for Patients with Recurrent Head and Neck Cancer: Implications for Randomized Trials

G. Poissonnet, O. Dassonville, F. Demard, 2001, Oncology.

Is extracapsular tumour spread a prognostic factor in patients with early breast cancer?

X. Pivot, J. Sautière, M. Demarchi, 2013, International Journal of Clinical Oncology.

Primary lung sarcomas: long survivors obtained with iterative complete surgery.

N. Magné, P. Marcy, X. Pivot, 2001, Lung cancer.

Age, Neurological Status MRC Scale, and Postoperative Morbidity are Prognostic Factors in Patients with Glioblastoma Treated by Chemoradiotherapy

X. Pivot, T. Moulin, E. Magnin, 2016, Clinical Medicine Insights. Oncology.

Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project

V. Torri, X. Pivot, G. Bocci, 2019, Advances in Therapy.

Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer

F. Kleinclauss, X. Pivot, Thierry Nguyen, 2012, Clinical Medicine Insights. Oncology.

Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study

S Pili-Floury, B. Chauffert, P. Muret, 2011, British Journal of Cancer.

Splenic lymphoma with villous lymphocytes: dissociated response with fludarabin.

X. Pivot, A. Thyss, M. Schneider, 1999, Hematology and Cell Therapy.

A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results.

V. Semiglazov, X. Pivot, S. Chatterjee, 2018, European journal of cancer.

Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from MONALEESA-3

P. Neven, X. Pivot, G. Jerusalem, 2018, Geburtshilfe und Frauenheilkunde.

Manual injection of subcutaneous trastuzumab vs intravenous infusion for HER2-positive early breast cancer: a time-and-motion study

N. Hauser, X. Pivot, E. Jakobsen, 2013 .

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.

L. Fallowfield, G. Curigliano, S. Verma, 2013, The Lancet. Oncology.

Cost–utility analyses of drug therapies in breast cancer: a systematic review

Bernhard Holzner, Georg Kemmler, G. Kemmler, 2016, Breast Cancer Research and Treatment.

Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study.

M. Espié, D. Spaeth, X. Pivot, 2017, European journal of cancer.

Incidence and risk factors of anemia in patients with early breast cancer treated by adjuvant chemotherapy.

X. Pivot, C. Villanueva, L. Chaigneau, 2012, Breast.

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes

G. Hortobagyi, H. Gómez, Bing-he Xu, 2010, Breast Cancer Research and Treatment.

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

M. Espié, D. Khayat, G. Romieu, 2013, The Lancet. Oncology.

Comprehensive molecular characterization of mitochondrial genomes in human cancers

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2017, bioRxiv.

A Randomized Phase I Pharmacokinetic Study Comparing Biosimilar Candidate SB3 and Trastuzumab in Healthy Male Subjects.

X. Pivot, G. Golor, E. Curtit, 2016, Clinical therapeutics.

Appropriate cytotoxic drugs usages in solid tumors: Impact of appropriate use referentials

X. Pivot, P. Arveux, S. Limat, 2012 .

Author Correction: Pan-cancer analysis of whole genomes

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2023, Nature.

Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France

T. Conroy, M. Ychou, F. Penault-Llorca, 2021, ESMO Open.

Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol

T. Petit, X. Pivot, M. Demarchi, 2020, Frontiers in Oncology.

Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study

A. Manikhas, X. Pivot, K. Jung, 2022, Breast.

Phase III Randomized Trial of Sunitinib (SU) vs. Capecitabine (C) in Patients (Pts) with Previously Treated HER2-Negative Advanced Breast Cancer (ABC).

H. Iwata, T. Tabei, K. Kern, 2009 .

New Microtubule Inhibitors in Breast Cancer

X. Pivot, C. Villanueva, F. Bazán, 2013, Current Breast Cancer Reports.

A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients.

X. Pivot, J. Lotz, A. Chan, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Novel Cytotoxic Agents in Chemotherapy-resistant Metastatic Breast Cancer – The Epothilones

X. Pivot, C. Borg, Thierry Nguyen, 2008 .

A multicenter phase II study of XRP 6258 administered as a 1h i . v . infusion every 3 weeks in taxane-resistant metastatic breast cancer patients

X. Pivot, J. Lotz, A. Chan, 2008 .

The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer (Review).

G. Hortobagyi, X. Pivot, L. Asmar, 1999, International journal of oncology.

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.

D. Miles, X. Pivot, A. Chan, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Sex differences in oncogenic mutational processes

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2019, Nature Communications.

Clinically Translatable Transcrocetin Delivery Platform for Correction of Tumor Hypoxia and Enhancement of Radiation Therapy Effects.

X. Pivot, A. Grabowska, P. Clarke, 2023, Small.

Cancer screening in France: third edition of the EDIFICE survey

J. Blay, X. Pivot, C. Touboul, 2015, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Breast cancer screening controversy: too much or not enough?

J. Blay, X. Pivot, C. Touboul, 2015, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Organizing medical oncology care at a regional level and its subsequent impact on the quality of early breast cancer management: a before-after study

X. Pivot, A. Woronoff, S. Limat, 2014, BMC Health Services Research.

Concomitant twice‐a‐day radiotherapy and chemotherapy in unresectable head and neck cancer patients: A long‐term quality of life analysis

P. Marcy, F. Demard, X. Pivot, 2001, Head & neck.

A new era for treatment development in HER2-positive breast cancer.

D. Cox, X. Pivot, 2018, The Lancet. Oncology.

Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.

V. Semiglazov, X. Pivot, S. Chatterjee, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study.

M. Espié, D. Khayat, G. Romieu, 2015, European journal of cancer.

Optimal Physicochemical Properties of Antibody–Nanoparticle Conjugates for Improved Tumor Targeting

X. Pivot, E. Moeglin, J. Goetz, 2022, Advanced materials.

Phase II Trial of Paclitaxel–Epirubicin in Patients With Recurrent Soft-Tissue Sarcoma

X. Pivot, J. Bay, M. Mita, 2002, American journal of clinical oncology.

P4-17-03: Incidence Rate of Asymptomatic Brain Metastases in Patients with HER2+ Metastatic Breast Cancer Screened for EGF111438/CEREBEL Study.

A. Manikhas, X. Pivot, R. Coleman, 2011 .

First-Line Vinorelbine-Mitoxantrone Combination in Metastatic Breast Cancer Patients Relapsing after an Adjuvant Anthracycline Regimen: Results of a Phase II Study

A. Le Cesne, X. Pivot, T. Tursz, 1998, Oncology.

Early skeletal muscle deconditioning and reduced exercise capacity during (neo)adjuvant chemotherapy in patients with breast cancer

X. Pivot, T. Hureau, F. Favret, 2022, Cancer.

Impact of glycosylation on the effect of cytokines. A special focus on oncology.

N. Magné, X. Pivot, G. Milano, 2002, European cytokine network.

Lack of adaptation to severe malnutrition in elderly patients.

X. Pivot, P. Rampal, R. Al-Jaouni, 2002, Clinical nutrition.

Exacerbated central fatigue and reduced exercise capacity in early-stage breast cancer patients treated with chemotherapy

X. Pivot, T. Hureau, F. Favret, 2023, European Journal of Applied Physiology.

Protective effect of intra-peritoneal epinephrine on postoperative renal function after cisplatin-based intra-peritoneal intra-operative chemotherapy.

B. Chauffert, X. Pivot, B. Royer, 2011, European journal of obstetrics, gynecology, and reproductive biology.

Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial

X. Pivot, I. Ray-Coquard, T. Bachelot, 2012, BMC Cancer.

154P Five-year follow-up of the phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in patients with HER2 positive early or locally advanced breast cancer

X. Pivot, M. Wojtukiewicz, Jinseon Lee, 2021, Annals of Oncology.

GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients

G. Thomas, D. Cox, H. Blanché, 2016, Oncotarget.

Evaluation of trastuzumab (Herceptin®), docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer

J. Jassem, A. Wardley, X. Pivot, 2007 .

Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer

J. Ahn, G. Lyman, G. Curigliano, 2023, JAMA network open.

Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab.

M. Espié, G. Romieu, I. Pauporté, 2018, Breast.

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.

X. Pivot, K. Jung, M. De Laurentiis, 2017, European journal of cancer.

Adjuvant Trastuzumab Is Required in Human Epidermal Growth Factor Receptor 2-Positive Node-Negative Breast Cancer Patients Regardless of Tumour Size

T. Petit, X. Pivot, L. Bender, 2020, Journal of breast cancer.

Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

P. Neven, F. Esteva, X. Pivot, 2019, Annals of Oncology.

Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC).

D. Amadori, M. Campone, A. Wardley, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical activity of ixabepilone, a novel epothilone b analog, across the breast cancer disease continuum

M. Piontek, E. Kubista, X. Pivot, 2008 .

LBA11 Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer

J. Abraham, H. Earl, H. Joensuu, 2021, Annals of Oncology.

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of squamous cell carcinoma of the head and neck.

X. Pivot, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity.

E. Tartour, X. Pivot, J. Pallandre, 2016, Cancer research.

A prognostic factor (PF) index for overall survival in a HER2-negative endocrine-resistant metastatic breast cancer (MBC) population: Analysis from the ATHENA trial.

X. Pivot, J. Pierga, I. Smith, 2013 .

Immunomodulatory Effects of Everolimus in a Long Responsive Patient With Metastatic Renal Cell Carcinoma

X. Pivot, C. Borg, B. Royer, 2014, Journal of immunotherapy.

A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage.

X. Pivot, G. Milano, P. Canal, 2000, European journal of cancer.

Low correlation between Ki67 assessed by qRT-PCR in Oncotype Dx score and Ki67 assessed by Immunohistochemistry

X. Pivot, C. Borg, M. Paillard, 2022, Scientific Reports.

Arthralgia and aromatase inhibitors.

X. Pivot, C. Prati, D. Wendling, 2014, Joint, bone, spine : revue du rhumatisme.

Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study

J. Blay, A. Lluch, S. Verma, 2014, BMC Cancer.

Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: An update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC)

C. Geyer, S. Loibl, M. Untch, 2019, Annals of Oncology.

Abstract P3-15-04: A French prospective pilot study to identify dihydropyrimidine dehydrogenase (DPD) deficiency in breast cancer patients receiving capecitabine

F. Pinguet, J. Bonneterre, G. Romieu, 2013 .

X. Pivot, B. Degano, D. Vernerey, 2017, BMC Cancer.

Lung cancer risks, beliefs and healthcare access among the underprivileged

J. Blay, X. Pivot, C. Touboul, 2015, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Endpoints in cancer clinical trials.

X. Pivot, C. Borg, F. Fiteni, 2014, Journal of visceral surgery.

[Combination of mitoxantrone-vinorelbine as first-line chemotherapy for metastatic breast carcinoma].

M. Namer, X. Pivot, J. Ferrero, 1995, Bulletin du Cancer.

Cerebel (EGF111438): An Open Label Randomized Phase III Study Comparing the Incidence of CNS Metastases in Patients (PTS) with HER2+ Metastatic Breast Cancer (MBC), Treated with Lapatinib Plus Capecitabine (LC) Versus Trastuzumab Plus Capecitabine (TC)

M. Desilvio, V. Semiglazov, X. Pivot, 2012 .

Sequential taxane and anthracycline-containing neoadjuvant regimens: the sequential order impact.

X. Pivot, A. Llombart-Cussac, J. Sautière, 2011, Breast.

Pembrolizumab in the Treatment of Breast Cancer.

X. Pivot, 2022, The New England journal of medicine.

Why the results of adjuvant pertuzumab in HER2-positive early breast cancer has been received as a mitigate success?

D. Cox, X. Pivot, J. Gligorov, 2017, Chinese clinical oncology.

Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort.

D. Cox, H. Bonnefoi, G. Romieu, 2017, European journal of cancer.

Challenges in the implementation of trastuzumab biosimilars: an expert panel’s recommendations

J. Blay, X. Pivot, P. Fumoleau, 2015, Anti-cancer drugs.

Ixabepilone, a novel epothilone analog in the treatment of breast cancer.

X. Pivot, C. Borg, Thierry Nguyen, 2008, Expert Opinion on Investigational Drugs.

Adverse events with pertuzumab and trastuzumab: Evolution during treatment with and without docetaxel in CLEOPATRA.

J. Baselga, S. Swain, X. Pivot, 2012 .

[Epidermal growth factor receptors (EGFR): a new target for anticancer therapy].

X. Pivot, A. Dufresne, M. Gainet, 2003, Cancer Radiothérapie.

299PEribulin is safe and efficient in metastatic breast cancer in elderly patients. Results from the REPROLINE multicentric retro-prospective cohort

M. Campone, X. Pivot, O. Trédan, 2017 .

Transmission of breast cancer polygenic risk based on single nucleotide polymorphisms.

D. Cox, X. Pivot, P. Heudel, 2018, Breast.

Impact of general practitioners' sex and age on systematic recommendation for cancer screening

J. Blay, X. Pivot, J. Morère, 2011, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Liver Metastases from Head and Neck Squamous Cell Carcinomas: Radiological and Biological Features

N. Magné, G. Poissonnet, P. Marcy, 2004, Oncology Research and Treatment.

Prostate cancer screening: contrasting trends

X. Pivot, J. Blay, C. Touboul, 2015, Cancer Causes & Control.

Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis.

X. Pivot, G. Milano, P. Canal, 1998, European journal of cancer.

990PDIMPACT OF CLINICAL PRACTICE GUIDELINE'S ON MEDICAL PRACTICE AND SURVIVAL FOR HEAD AND NECK CANCER MANAGEMENT IN FISRT LINE TREATMENT (N = 1121 PATIENTS).

X. Pivot, I. Ray-Coquard, E. Reyt, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Beliefs and behavior regarding e-cigarettes in a large cross-sectional survey

J. Blay, X. Pivot, S. Couraud, 2018, Preventive medicine reports.

Incidental axillary dose delivery to axillary lymph node levels I–III by different techniques of whole-breast irradiation: a systematic literature review

X. Pivot, C. Mathelin, G. Noel, 2021, Strahlentherapie und Onkologie.

MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer

P. Neven, G. Sledge, X. Pivot, 2019, Annals of Oncology.

Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting

G. Bonamy, M. Derde, X. Pivot, 2022, JAMA oncology.

Response Rates: A Valuable Signal of Promising Activity?

X. Pivot, C. Villanueva, F. Bazán, 2009, Cancer journal.

Uptake of breast cancer screening in women aged over 75years: a controversy to come?

J. Blay, X. Pivot, J. Morère, 2011, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Organized colorectal cancer screening programmes: how to optimize efficiency in the general population

J. Blay, X. Pivot, J. Morère, 2011, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.

A. Goldhirsch, G. Curigliano, M. Collier, 2013, Breast.

Predictors of re-excision for positive or close margins in breast-conservation therapy for pT1 tumors.

X. Pivot, R. Ramanah, J. Sautière, 2008, American journal of surgery.

Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial.

M. Espié, D. Khayat, G. Romieu, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort

G. Thomas, D. Cox, H. Blanché, 2017, npj Breast Cancer.

Enterocolitis in Patients with Cancer Treated with Docetaxel.

Nadine Houédé, X. Pivot, N. Houédé, 2018, Anticancer research.

A dose-escalating study of XRP6258 in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy: Preliminary results.

J. Machiels, M. Campone, X. Pivot, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy

P. Neven, G. Sledge, X. Pivot, 2017 .

F12 How safe is bevacizumab for elderly patients

X. Pivot, C. Villanueva, E. Curtit, 2009 .

Critical appraisal of health-state utility values used in breast cancer-related cost–utility analyses

R. Viney, G. Kemmler, X. Pivot, 2017, Breast Cancer Research and Treatment.

5077 Lapatinib plus letrozole vs. letrozole alone in patients (pts) with endocrine sensitive, HER2+, previously untreated metastatic breast cancer (MBC) with multiple (>3sites) or liver metastases

S. Johnston, X. Pivot, J. Maltzman, 2009 .

Neuropilin-2 and epithelial to mesenchymal transition in colorectal cancer cells.

M. Klagsbrun, X. Pivot, C. Grandclément, 2010 .

Social stratification, risk factor prevalence and cancer screening attendance

J. Blay, X. Pivot, C. Touboul, 2015, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns

Nuno A. Fonseca, Benjamin J. Raphael, Allison P. Heath, 2020, Nature Communications.

Toward Clinical Transfer of Tumor‐Targeted Ultrasmall Inorganic Nanoparticles

O. Tillement, X. Pivot, S. Harlepp, 2023, Advanced Therapeutics.

Final Overall Survival (OS) Results from the Randomised, Double-Blind, Placebo-Controlled, Phase III AVADO Study of Bevacizumab (BV) Plus Docetaxel (D) Compared with Placebo (PL) Plus D for the First-Line Treatment of Locally Recurrent (LR) or Metastatic Breast Cancer (mBC).

N. Harbeck, D. Miles, L. Dirix, 2009 .

Oncotargets and Therapy Dovepress Clinical Impact of Targeted Therapies in Patients with Metastatic Clear-cell Renal Cell Carcinoma

F. Kleinclauss, X. Pivot, M. Paillard, 2022 .

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences

E. Birney, M. Ringnér, A. Børresen-Dale, 2019, Nature.

5025 A dose escalating study of cabazitaxel (XRP6258) in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy

J. Machiels, M. Campone, X. Pivot, 2009 .

Factors influencing colorectal cancer screening participation rates in 2016.

J. Blay, X. Pivot, S. Couraud, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Four-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer in neoadjuvant setting.

H. Rugo, G. Lyman, G. Curigliano, 2020 .

Safety of First-Line Letrozole Compared with Lapatinib Plus Letrozole in Patients with Postmenopausal Hormone Receptor Positive Metastatic Breast Cancer: EGF30008 Study.

A. Makris, X. Pivot, L. Fehrenbacher, 2009 .

Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practice

X. Pivot, C. Borg, Stefano Kim, 2021, Quality of Life Research.

A Retrospective Study of Bifractionated CPT-11 With LF5FU Infusion (FOLFIRI-3) in Colorectal Cancer Patients Pretreated With Oxaliplatin and CPT-11 Containing Chemotherapies

X. Pivot, C. Borg, Thierry Nguyen, 2008, American journal of clinical oncology.

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.

M. Parmar, J. Mackey, D. Cameron, 2013, The Lancet. Oncology.

Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.

A. Goldhirsch, G. Curigliano, M. Collier, 2013, Breast.

Abstract P2-16-04: Plasma Biomarker Analyses in the AVADO Phase III Randomized Study of First-Line Bevacizumab + Docetaxel in Patients with Human Epidermal Growth Factor Receptor (HER) 2-Negative Metastatic Breast Cancer

D. Miles, L. Dirix, X. Pivot, 2010 .

Impact of platinum complexes on dihydropyrimidine dehydrogenase activity in 5-fluorouracil-treated patients.

N. Magné, F. Demard, X. Pivot, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Predictors of re-excision for positive or close margins in breast-conservation therapy for pT1 tumors.

X. Pivot, R. Ramanah, J. Sautière, 2008, American journal of surgery.

Intraoperative chemotherapy with cisplatin and epinephrine after cytoreductive surgery in patients with recurrent ovarian cancer: a phase I study

B. Chauffert, X. Pivot, M. Demarchi, 2010, Anti-cancer drugs.

Analysis of spontaneous tumor-specific CD4 T cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response

E. Tartour, A. Cazes, X. Pivot, 2012 .

Melanoma risk‐takers: fathers and sons

X. Pivot, F. Grange, L. Mortier, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

Squamous cell carcinoma of the head and neck: ESMO clinical recommendations for diagnosis, treatment and follow-up.

X. Pivot, C. Villanueva, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Response Rates: A Valuable Signal of Promising Activity?

X. Pivot, C. Villanueva, F. Bazán, 2009, Cancer journal.

Abstract S5-3: PHARE Trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer

M. Espié, H. Bonnefoi, D. Khayat, 2012 .

Phare Trial Results Comparing 6 to 12 Months of Trastuzumab in Adjuvant Early Breast Cancer

M. Espié, H. Bonnefoi, D. Khayat, 2012 .

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences

E. Birney, M. Ringnér, A. Børresen-Dale, 2019, Nature.

A Combination of Native LC-MS Approaches for the Comprehensive Characterization of the Antibody-Drug Conjugate Trastuzumab Deruxtecan.

X. Pivot, S. Cianférani, H. Diemer, 2022, Frontiers in bioscience.

Cardiac safety of the lapatinib/letrozole combination as first-line therapy in patients (pts) with metastatic breast cancer (MBC).

H. Gómez, M. Koehler, S. Johnston, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line lapatinib combined with letrozole versus letrozole alone for hormone receptor positive (HR+) metastatic breast cancer (MBC): Subgroup analyses of borderline FISH+, IHC 2+, HER2 unknown (UNK), and treatment-naive (TN) populations from EGF30008.

H. Gómez, S. Johnston, X. Pivot, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dendritic cell and natural killer cell cross-talk: a pivotal role of CX3CL1 in NK cytoskeleton organization and activation.

L. Zitvogel, B. Ryffel, J. Strominger, 2008, Blood.

Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients

T. Petit, X. Pivot, M. Velten, 2019, Breast Cancer Research and Treatment.

[Cancer screening in France: 10 years of analysis of behaviours by the EDIFICE surveys].

J. Blay, X. Pivot, S. Couraud, 2017, Bulletin du cancer.

Prevention and screening

S. Duffy, A. Carrato, M. Kusumoto, 2012 .